Begoña Jiménez

828 total citations
29 papers, 531 citations indexed

About

Begoña Jiménez is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Begoña Jiménez has authored 29 papers receiving a total of 531 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 9 papers in Cancer Research. Recurrent topics in Begoña Jiménez's work include HER2/EGFR in Cancer Research (9 papers), Breast Cancer Treatment Studies (7 papers) and PI3K/AKT/mTOR signaling in cancer (6 papers). Begoña Jiménez is often cited by papers focused on HER2/EGFR in Cancer Research (9 papers), Breast Cancer Treatment Studies (7 papers) and PI3K/AKT/mTOR signaling in cancer (6 papers). Begoña Jiménez collaborates with scholars based in Spain, United Kingdom and United States. Begoña Jiménez's co-authors include Emilio Alba, Nuria Ribelles, Bella Pajares, Alfonso Sánchez‐Muñoz, José Trigo, Udai Banerji, Antonia Márquez, Martina Álvarez, Desamparados Roda and M.I. Sáez and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Begoña Jiménez

27 papers receiving 525 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Begoña Jiménez Spain 15 272 176 174 116 65 29 531
Greg Dyson United States 13 192 0.7× 219 1.2× 114 0.7× 172 1.5× 21 0.3× 36 561
Jana Halámková Czechia 10 191 0.7× 191 1.1× 206 1.2× 108 0.9× 67 1.0× 36 553
Jinan Ma China 12 174 0.6× 143 0.8× 111 0.6× 101 0.9× 29 0.4× 43 397
Ran Xie United States 12 221 0.8× 295 1.7× 141 0.8× 185 1.6× 50 0.8× 32 676
Maura O’Neil United States 16 245 0.9× 275 1.6× 199 1.1× 65 0.6× 143 2.2× 46 795
Mohamed A. Gouda United States 13 228 0.8× 166 0.9× 219 1.3× 166 1.4× 61 0.9× 58 546
Leila Dorling United Kingdom 12 204 0.8× 96 0.5× 212 1.2× 127 1.1× 69 1.1× 18 541
Marko Buta Serbia 12 143 0.5× 161 0.9× 108 0.6× 143 1.2× 53 0.8× 42 489
Johannes Brägelmann Germany 16 352 1.3× 557 3.2× 296 1.7× 313 2.7× 59 0.9× 39 1.0k
Tomohiro Nogami Japan 11 232 0.9× 134 0.8× 148 0.9× 98 0.8× 34 0.5× 32 441

Countries citing papers authored by Begoña Jiménez

Since Specialization
Citations

This map shows the geographic impact of Begoña Jiménez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Begoña Jiménez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Begoña Jiménez more than expected).

Fields of papers citing papers by Begoña Jiménez

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Begoña Jiménez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Begoña Jiménez. The network helps show where Begoña Jiménez may publish in the future.

Co-authorship network of co-authors of Begoña Jiménez

This figure shows the co-authorship network connecting the top 25 collaborators of Begoña Jiménez. A scholar is included among the top collaborators of Begoña Jiménez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Begoña Jiménez. Begoña Jiménez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Morocho, Vladimir, et al.. (2025). Biological Activity and Chemical Composition of Essential Oil from Leaves and Fruits of Zanthoxylum mantaro (J.F.Macbr.) J.F.Macbr. Antibiotics. 14(3). 216–216. 1 indexed citations
2.
Pernas, Sònia, Esther Sanfeliu, Guillermo Villacampa, et al.. (2024). Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy. npj Breast Cancer. 10(1). 101–101.
3.
André, Thierry, Susana Banerjee, Dominique Berton, et al.. (2022). Abstract 5135: Antitumor activity of dostarlimab by PD-L1 and tumor mutation burden (TMB) in patients (pts) with mismatch repair deficient and proficient (dMMR and MMRp) tumors in the GARNET trial. Cancer Research. 82(12_Supplement). 5135–5135. 3 indexed citations
4.
Jiménez, Begoña, Ana Godoy-Ortíz, Esperanza Torres, et al.. (2021). Significant Decrease in Annual Cancer Diagnoses in Spain during the COVID-19 Pandemic: A Real-Data Study. Cancers. 13(13). 3215–3215. 28 indexed citations
5.
6.
7.
8.
Pérez-López, Raquel, Desam Roda, Begoña Jiménez, et al.. (2017). High frequency of radiological differential responses with poly(ADP-Ribose) polymerase (PARP) inhibitor therapy. Oncotarget. 8(61). 104430–104443. 4 indexed citations
9.
Roda, Desamparados, Begoña Jiménez, & Udai Banerji. (2015). Are Doses and Schedules of Small-Molecule Targeted Anticancer Drugs Recommended by Phase I Studies Realistic?. Clinical Cancer Research. 22(9). 2127–2132. 20 indexed citations
10.
Prat, Aleix, Patricia Galván, Begoña Jiménez, et al.. (2015). Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay. Clinical Cancer Research. 22(3). 560–566. 64 indexed citations
11.
Rafii, Saeed, Desamparados Roda, Elena Geuna, et al.. (2015). Higher Risk of Infections with PI3K–AKT–mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical Trials. Clinical Cancer Research. 21(8). 1869–1876. 28 indexed citations
12.
Geuna, Elena, Desamparados Roda, Saeed Rafii, et al.. (2015). Complications of hyperglycaemia with PI3K–AKT–mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials. British Journal of Cancer. 113(11). 1541–1547. 27 indexed citations
13.
Basu, Bristi, Mona Parmar, Andrea Turner, et al.. (2014). Phase I Multicentre Tax-Torc Trial of the Dual Mtorc1/2 Inhibitor Azd2014 (A) Plus Weekly Paclitaxel (P) in Patients (Pts) with Solid Tumours (Crukd/12/013). Annals of Oncology. 25. iv156–iv156. 1 indexed citations
14.
Ribelles, Nuria, José M. Jerez, Bella Pajares, et al.. (2013). Pattern of recurrence of early breast cancer is different according to intrinsic subtype and proliferation index. Breast Cancer Research. 15(5). R98–R98. 89 indexed citations
15.
Pajares, Bella, José Trigo, Martina Álvarez, et al.. (2013). Concurrent radiotherapy plus epidermal growth factor receptor inhibitors in patients with human papillomavirus-related head and neck cancer. Clinical & Translational Oncology. 16(4). 418–424. 8 indexed citations
16.
Pajares, Bella, Esperanza Torres, José Trigo, et al.. (2012). Tyrosine kinase inhibitors and drug interactions: a review with practical recommendations. Clinical & Translational Oncology. 14(2). 94–101. 29 indexed citations
17.
Sánchez‐Muñoz, Alfonso, Elísabeth Pérez-Ruiz, M.I. Sáez, et al.. (2011). Limited impact of palliative chemotherapy on survival in advanced solid tumours in patients with poor performance status. Clinical & Translational Oncology. 13(6). 426–429. 18 indexed citations
18.
Pajares, Bella, Esperanza Torres, Begoña Jiménez, et al.. (2011). Multimodal treatment of desmoid tumours: the significance of local control. Clinical & Translational Oncology. 13(3). 189–193. 9 indexed citations
19.
Sánchez‐Muñoz, Alfonso, Elísabeth Pérez-Ruiz, Nuria Ribelles, et al.. (2010). Outcome of Small Invasive Breast Cancer with No Axillary Lymph Node Involvement. The Breast Journal. 17(1). 32–38. 8 indexed citations
20.
Sánchez‐Muñoz, Alfonso, Elísabeth Pérez-Ruiz, Begoña Jiménez, et al.. (2009). Targeted therapy of metastatic breast cancer. Clinical & Translational Oncology. 11(10). 643–650. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Greg Dyson Breakdown of academic impact, for papers by Jana Halámková Breakdown of academic impact, for papers by Jinan Ma Breakdown of academic impact, for papers by Ran Xie Breakdown of academic impact, for papers by Maura O’Neil Breakdown of academic impact, for papers by Mohamed A. Gouda Breakdown of academic impact, for papers by Leila Dorling Breakdown of academic impact, for papers by Marko Buta Breakdown of academic impact, for papers by Johannes Brägelmann Breakdown of academic impact, for papers by Tomohiro Nogami
Rankless by CCL
2026